Madison Jones

Cooley advised Zoetis on its $1.35 billion aggregate principal amount of investment-grade unsecured senior notes, $600 million of 5.400% senior notes due 2025, and $750 million of 5.600% senior notes due 2032. Zoetis is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. Eric Blanchard and Madison Jones led the Cooley team.

Cooley advised the placement agents in Scholar Rock’s $205 million registered direct offering, with J.P. Morgan as lead placement agent and Piper Sandler as co-placement agent . Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Partners Daniel Goldberg, Div Gupta and Madison Jones led the Cooley team.

Cooley advised MaxCyte on its $201.8 million initial public offering of 15,525,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. MaxCyte, whose securities now trade on the Nasdaq Global Select Market under the symbol “MXCT,” also trades on the London Stock Exchange under the symbols "MXCT" and "MXCN." MaxCyte is a leading provider of cell-engineering platform technologies. Partners Christian Plaza, Brian Leaf and Claire Keast-Butler led the Cooley team.

Cooley advised the underwriters on Werewolf Therapeutics’ $120 million initial public offering of 7,500,000 shares of common stock. Jefferies, SVB Leerink and Evercore Group acted as joint book-running managers. Werewolf Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol HOWL, is an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Partners Brent Siler, Madison Jones and Div Gupta led the Cooley team.

Cooley advised the underwriters on Olink Holding’s $406 million initial public offering of 20,294,116 American Depositary Shares, which includes the full exercise of the underwriters’ option to purchase additional shares. Goldman Sachs and Morgan Stanley acted as lead book-running managers for the offering and SVB Leerink acted as a joint book-running manager for the offering. Olink, whose securities now trade on the Nasdaq Global Market under the symbol OLK, is a company dedicated to accelerating proteomics together with the scientific community. Partners Richard Segal, Charlie Kim, Eric Blanchard and Madison Jones led the Cooley team.